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ABSTRACT 
Background & Aims The pathogenesis of hepatic encephalopathy (HE) is multifactorial and often associated with the 
development of brain oedema. In addition to ammonia playing a central role, systemic oxidative stress is believed to 
aggravate the neuropsychological effects of ammonia in patients with chronic liver disease (CLD). The aim of this study 
was to (i) induce systemic oxidative stress in hyperammonaemic portacaval anastomosed (PCA) rats by inhibiting the 
antioxidant glutathione using Dimethyl maleate (DEM) and (ii) investigate whether a synergistic relationship between 
ammonia and oxidative stress contributes to the pathogenesis of brain oedema in CLD. Methods Four-week PCA and 
sham-operated rats received DEM (0.4–4 mg/kg/day) for the last 10 days before sacrifice when oxidative stress markers 
[reactive oxygen species (ROS) and malondialdehyde (MDA)] were assessed in blood and frontal cortex. Brain water 
content was measured using a specific gravimetric technique. Results Dimethyl maleate induced an increase in ROS and 
MDA in the blood, but not in the brain, of the PCA rats, compared with non-treated PCA rats. This was accompanied with 
an increase in brain water content (PCA+DEM: 78.45 ± 0.13% vs. PCA: 77.38 ± 0.11%, P < 0.001). Higher doses of DEM 
induced systemic oxidative stress in sham-operated controls, but brain oedema did not develop. Conclusions Dimethyl 
maleate provoked systemic, not central, oxidative stress in PCA rats, resulting in the development of brain oedema. 
Independently, hyperammonaemia and systemic oxidative stress do not precipitate brain oedema; therefore, our findings 
sustain that a synergistic effect between hyperammonaemia and systemic oxidative stress is responsible for the development 
of brain oedema in HE. 
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INTRODUCTION 
Hepatic encephalopathy (HE) is a debilitating condition affecting close to 30–84% of patients with chronic liver disease 
(CLD). This neuropsychiatric disorder is characterized by cognitive, psychiatric and motor disturbances and is primarily 
divided into overt (confusion, disorientation, ataxia and coma) and covert (reduced psychomotor speed, increased reaction 
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time, sensory abnormalities, poor concentration) [1]. Contrary to overt HE, the diagnosis of covert HE is not clinically 
evident and requires sensitive psychometric and neurophysiological testing [2]. The burden of covert HE is 
multidimensional, affecting the patient's quality of life (ability to work and drive a car) and economically draining on health 
care systems [3]. More importantly, covert HE places patients at a higher risk of developing overt HE with increased 
mortality [4]. 
The neuropathology of HE in CLD reveals morphological changes in astrocytes, including cell swelling, which 
consequently leads to brain oedema [5]. This feature is commonly observed in both patients and rats with cirrhosis suffering 
from covert HE [6-11], however, HE also exists in the absence of brain oedema [12, 13]. Brain oedema has demonstrated to 
correlate with the severity of the disease [15, 14, 16], and has shown to improve following liver transplantation [6]. 
Liver failure induces hyperammonaemia, which consequently leads to neurotoxic levels of ammonia, a principle factor long 
considered to be implicated in the pathogenesis of HE. However, a correlation between levels of blood ammonia and 
severity of HE in CLD remains controversial [17-21], suggesting other pathogenic factors are involved. Recently, it has 
been postulated that systemic oxidative stress can exacerbate the neurological effects of ammonia and play an important role 
in the pathogenesis of HE in CLD [22, 23]. Oxidative stress, a systemic phenomenon correlated with severity of liver 
disease [24, 25], is an important condition present in patients with cirrhosis, and occurs due to an imbalance between the 
activities of pro-oxidants and antioxidants, leading to a surplus in reactive oxygen species (ROS). Pro-oxidants 
constitutively generate ROS, which are important for proper cell signalling and function whereas antioxidants are 
responsible for regulating the levels of ROS and thus maintain a healthy equilibrium. Disturbance in pro-oxidant/antioxidant 
harmony has been demonstrated in the setting of liver disease. Xanthine oxidase, a liver derived pro-oxidant enzyme which 
produces ROS following oxidation of hypoxanthine to xanthine and to uric acid, has been found to be increased in 
circulation in both patients with CLD and cirrhotic rats [26, 27]. In addition, we recently demonstrated that by inhibiting 
xanthine oxidase with allopurinol, circulating levels of ROS were attenuated, brain oedema was prevented and HE was 
improved [27]. Furthermore, glutathione (GSH), an important antioxidant synthesized by the liver, has been found to be 
decreased in cirrhosis [27-29]. 
Contrary with cirrhotic rats, rats with portacaval anastomosis (PCA) develop hyperammonaemia in the absence of intrinsic 
hepatocellular disease [30] and neither brain oedema nor any evidence of oxidative stress has been observed [27, 31]. The 
aim of this study was to induce systemic oxidative stress in PCA rats and investigate whether a synergistic relationship 
between ammonia and oxidative stress is key in the pathogenesis of brain oedema in CLD. To induce oxidative stress, PCA 
rats were treated with dimethyl maleate (DEM), an irreversible GSH inhibitor [32]. 
MATERIALS AND METHODS 
Animal model and experimental protocol 
Adult male Sprague-Dawley rats weighing 200–225 g were anesthetized with isoflurane, and an end-to-side PCA was 
performed [27]. Starting at day 18 after surgery, both PCA and sham-operated controls were administered DEM once daily 
(4, 3, 2, 1 or 0.4 mg/kg diluted in 1 ml/kg saline; intraperitoneally) until day 28 when they were sacrificed. Vehicle-treated 
sham and PCA rats received equivalent volumes of saline. Experiments were conducted following the Guidelines of 
Canadian Council on Animal Care and were approved by the Animal Protection Committee of CRCHUM. 
Markers of oxidative stress 
Circulating ROS were evaluated following the oxidation of dichlorofluorescein diacetate (Invitrogen, Carlsbad, CA, USA) 
to dichlorofluorescein as previously described [27]. Plasmatic and/or frontal cortex lipid peroxidation was estimated by 
measuring the levels of malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) formation. MDA levels were measured 
using TBARS Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA), according to the manufacturer's protocol. 
Total GSH was measured in the plasma and frontal cortex tissue, based on the sulphhydryl group oxidation by DTNB (5,5′-
dithiobis-2-nitrobenzoic acid), which forms a yellow product (5-thio-2-nitrobenzoic acid, TNB) that is measured 
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spectrophotometrically. Oxidized GSH was previously reduced to GSH by glutathione reductase. Plasma and brain samples 
were extracted in five volumes of sulphosalicylic acid 5%, then homogenized and centrifuged 10 min at 13 000g. 10 μl of 
the supernatant was incubated for 5 min with 150 μl sodium phosphate-buffer 95 mM containing EDTA 0.95 mM, 
glutathione reductase 0.115 U/ml and DTNB 0.031 mg/ml. The reaction was started by adding 50 μl reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) 0.038 mg/ml, the oxidation of which was followed at 412 nm for 32 min. Total 
GSH concentration was calculated based on a standard curve with known concentrations of GSH. 
For HNE assessment, frontal cortex was homogenized in lysis buffer (50 mM Tris pH 7.5, 1 mM EDTA, 1/500 cold 
protease inhibitor cocktail). Homogenates were centrifuged 40 min at 13 000g at 4°C. The supernatant was taken and 
protein content was determined according to the method of Lowry et al. [33]. Samples containing 75 μg of cortex proteins 
were separated by 8% sodium dodecyl sulphate-polyacrylamide gels electrophoresis, and then transferred to polyvinylidene 
difluoride membranes. Membranes were blocked with 5% skim milk in TBS-T buffer (1 mM Tris pH = 7.5, 10 mM NaCl 
and 0.5% Tween 20) for 1 h at room temperature and followed by 1 h incubation with rabbit polyclonal anti-HNE antibody 
(Calbiochem, Darmstadt Germany) at a dilution of 1:1000. Membranes were washed three times in TBS-T buffer for 5 min 
and then incubated for 1 h at room temperature, with the corresponding secondary antibody labelled with horseradish 
peroxidase (Perkin-Elmer, Waltham, MA, USA) at a dilution of 1:10 000 and washed three times in TBS-T buffer for 
5 min. Immunoreactivity was detected with chemiluminescence reagent and probed on X-ray film. A monoclonal antibody 
to β-actin (Sigma, St-Louis, MO, USA) was used at a dilution of 1:200 000 as a control of protein loading. 
Brain water content 
Brain water content was measured using the sensitive densitometry technique. Frontal cortex was freshly dissected at 4°C 
and cut into 2 mm3 pieces. Tissue pieces were placed in density gradient columns and equilibrium point was recorded after 
2 min. Columns were made with different kerosene and bromobenzene mixtures and precalibrated with K2SO4 solutions of 
known densities. At least eight samples were measured in each rat. Water content was calculated based on tissue density, 
according to the formula described by Marmarou et al. [34]. 
Liver biochemistry 
Liver necrosis markers aspartate and alanine aminotransferase were measured using routine clinical biochemistry 
techniques. 
Ammonia 
Plasmatic ammonia levels were measured using a commercial kit (Sigma) according to the manufacturer's protocol. The kit 
is based on the reaction of ammonia with α-ketoglutarate and reduced nicotinamide adenine dinucleotidephosphate in the 
presence of L-glutamate dehydrogenase. Oxidation rate of reduced NADPH was recorded by the absorbance decrease at 
340 nm. Ammonia concentration was calculated according to the manufacturer's protocol. 
Statistical analysis 
Data are expressed as mean ± standard error of the mean. Significance of difference was tested with Anova, followed by 
Newman–Keuls post-test using GraphPad Prism4 (La Jolla, CA, USA). Probability values P < 0.05 were considered to be 
statistically significant. 
RESULTS 
Dimethyl maleate treatment 
It has previously been demonstrated that a single injection of DEM at doses up to 4 mg/kg administered to naïve rats was 
non-toxic and did not lead to mortality [32]. In our study, since oxidative stress is a chronic feature observed throughout the 
time course of cirrhosis [27], we aimed to induce long-term oxidative stress in PCA rats by injecting DEM daily for 10 days 
at different doses (4, 3, 2, 1 or 0.4 mg/kg). DEM at doses 4 and 3 mg/kg lead to 100% mortality in PCA rats before the end 
of the 10-day treatment (4 mg/kg resulted in death after 1–2 days of treatment, and 3 mg/kg resulted in death following 7–
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9 days of treatment), whereas DEM at doses 2, 1 and 0.4 mg/kg did not lead to mortality in PCA rats. No mortality occurred 
in sham-operated controls treated with DEM at doses 4, 3, 2, 1 and 0.4 mg/kg for the duration of the 10-day treatment. 
 
Dimethyl maleate induces systemic oxidative stress in portacaval anastomosis rats  
The efficacy of DEM treatment in inducing systemic ROS was assessed by measuring various markers of oxidative stress. A 
significant increase in plasma ROS was observed in PCA rats vs. sham-operated controls following DEM treatment at doses 
2 and 1 mg/kg, but not at 0.4 mg/kg (Fig. 1A). Continuing with the dose 1 mg/kg, DEM treatment led to a significant 
decrease in total GSH in PCA rats, but not in sham-operated controls compared with respective non-treated controls 
(Fig. 1B). MDA, a reliable marker of oxidative stress resulting from lipid peroxidation, was found to be significantly 

















Figure 1. (A) Circulating reactive oxygen species (ROS) in rats with portacaval anastomosis (PCA) and 
sham-operated controls treated and not treated with dimethyl maleate (DEM) at a dose of 2, 1 or 
0.4 mg/kg/day for 10 days; (B) plasmatic glutathione (GSH) and (C) malondialdehyde (MDA) in rats 
with PCA and sham-operated controls treated and not treated with DEM at a dose of 1 mg/kg/day for 
10 days. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, significantly different from all 
other groups. 
Dimethyl maleate induces brain oedema in portacaval anastomosis rats 
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Dimethyl maleate treatment to PCA rats lead to a significant increase in brain water content in frontal cortex compared with 
non-treated PCA rats (PCA + DEM: 78.06 ± 0.09% vs. non-treated PCA: 77.53 ± 0.12%, P < 0.05) and compared with 







Figure 2. Frontal cortex water content in rats with portacaval anastomosis (PCA) and sham-operated 
controls treated and not treated with dimethyl maleate (DEM) at a dose of 1 mg/kg/day for 10 days. 
Data are expressed as mean ± SEM. *P < 0.05, significantly different from all other groups. 
Dimethyl maleate does not induce cerebral oxidative stress in portacaval anastomosis rats  
Dimethyl maleate treatment did not lead to a significant increase in oxidative stress markers (total GSH, MDA and HNE) in 
either the frontal cortex of PCA nor sham-operated controls (Fig. 3A–C). 
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Figure 3. (A) Cerebral glutathione (GSH); (B) malondialdehyde (MDA) and (C) 4-hydroxy-2- nonenal 
(HNE; representative immunoblotting images for each group along with densitometric quantification 
are shown) in rats with portacaval anastomosis (PCA) and sham-operated controls treated and not 
treated with dimethyl maleate (DEM) at a dose of 1 mg/kg/day for 10 days. Data are expressed as 
mean ± SEM. 
Dimethyl maleate does not affect ammonia levels and liver function 
Dimethyl maleate treatment did not induce hyperammonaemia in sham-operated controls, nor influence the blood ammonia 
levels in PCA rats. In addition, DEM treatment did not increase the levels of AST or ALT in both PCA and sham-operated 
controls (Table 1). 
Table 1. Hepatic function markers aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and ammonia 
levels in rats with portacaval anastomosis (PCA) and sham-operated controls treated and not treated with dimethyl maleate 




Data are expressed as mean ± SEM.  
a
P < 0.001, significantly vs. sham-operated rats. 
 
Systemic oxidative stress independently does not lead to brain oedema 
Contrary with doses 0.4, 1, 2 and 3 mg/kg, DEM at dose 4 mg/kg provoked a significant increase in plasma ROS in sham-
operated controls, which is similar to the increase in levels of ROS as those seen in PCA rats treated with DEM at a dose of 
1 mg/kg. However, the former was not accompanied with the apparition of brain oedema, as was observed in the DEM-
treated PCA rats (Fig. 4). 
Figure 4. Circulating reactive oxygen species (ROS) and frontal cortex water in rats with portacaval 
anastomosis (PCA) treated and not treated with dimethyl maleate (DEM) at a dose of 1 mg/kg/day 
for 10 days and sham-operated controls treated with dimethyl maleate (DEM) at a dose of 
4 mg/kg/day for 10 days. Data are expressed as percent change compared with non-treated sham-
operated controls. ROS percent change is represented on the left axis and traced with a full line, 
while brain oedema is represented on the right axis and traced with a dotted line. *P < 0.05, 
significantly vs. non-treated PCA rats. 
DISCUSSION 
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Dimethyl maleate treatment significantly resulted in a reduction in circulating levels of GSH in hyperammonaemic PCA 
rats, which in turn led to the induction of systemic, but not central, oxidative stress, and triggered the apparition of brain 
oedema. DEM-induced systemic oxidative stress, in the absence of hyperammonaemia, was not accompanied with presence 
of brain oedema sustaining that both hyperammonaemia and systemic oxidative stress are synergistically implicated in the 
pathogenesis of brain oedema in CLD. 
The aim of this study was to induce oxidative stress in hyperammonaemic PCA rats by targeting and diminishing the 
antioxidant GSH, a tripeptide formed of glutamate, cysteine and glycine, whose cysteine residue acts as an electron donor. 
By scavenging ROS, GSH is converted into oxidized glutathione and reduced back to GSH by glutathione reductase. GSH, 
primarily produced by the liver, has been found to be increased in early stages of cirrhosis [35] but is evidently diminished 
during late stages of liver disease [27-29]. However, in PCA rats, where the liver function is preserved, GSH levels are not 
affected [27]. To target the inhibition of GSH, we used DEM, a direct GSH inhibitor that acts by irreversibly conjugating 
the cysteine's sulphahydryl group. It has been previously demonstrated that a single dose of DEM (600 mg/kg) administered 
to naïve rats induces a transient (12 h) decrease in hepatic and cerebral GSH [36]. To simulate a chronic condition of 
oxidative stress (as observed during cirrhosis), daily injections of smaller doses of DEM were administered. Ten-day 
treatment of DEM, as low as 1 mg/kg, significantly diminished GSH levels in PCA rats. This resulted in the induction of 
oxidative stress in plasma, reflected with an increase in ROS and MDA. This same dose of DEM did not lead to similar 
results in sham-operated treated rats. Instead, a higher dose of DEM (4 mg/kg) was needed to attain a similar significant 
increase in ROS. This suggests that PCA rats demonstrate a higher susceptibility to a DEM-induced oxidative stress insult 
compared with sham-operated controls. The mechanisms underlying this susceptibility are unresolved, but the effect of 
chronic moderate elevated levels of ammonia in PCA rats may render the brain sensitive to insults. The mechanisms 
underlying increased brain sensitivity following chronic ammonia exposure merits to be further investigated. 
Ammonia has long been considered to play a major role in the pathogenesis of brain oedema and HE; however, its weak 
relationship with severity of HE suggests that other factors are involved. Our results suggest that systemic oxidative stress is 
a key factor, in addition to ammonia that precipitates brain oedema, since (i) hyperammonaemic PCA rats do not develop 
brain oedema and (ii) DEM-induced oxidative stress in sham-operated rats, which do not present hyperammonaemia, does 
not lead to brain oedema. This implies that neither oxidative stress nor ammonia independently induces brain oedema. PCA 
in the rat represents a type B HE model resulting from portal-systemic shunting in the absence of parenchymal liver disease. 
Therefore, in the absence of liver-derived factors like inflammation and oxidative stress, brain oedema does not develop as 
previously demonstrated [12, 13, 27]. Since DEM-induced oxidative stress in hyperammonaemic PCA rats lead to the 
development of brain oedema, this implies that a synergistic effect between ammonia and oxidative stress is required to 
cause an increase in brain water. 
These observations support our previous studies demonstrating that a synergistic effect between systemic oxidative stress 
and ammonia is imperative in the development of brain oedema in CLD [9, 27]. Furthermore, the clinical implications of 
this important synergy is sustained by a study from Montoliu et al. who elegantly demonstrated in cirrhotic patients with 
similar degrees of hypermamonaemia, that the detection of 3-nitrotyrosine in plasma distinguished covert HE cirrhotic 
patients from those without HE [37]. During liver disease, oxidative stress represents a systemic phenomenon [38], 
however, the pathophysiological significance of whether oxidative stress vs. ammonia is the ‘first’ or ‘second’ remains to be 
defined. 
Swelling of the brain in DEM-treated PCA rats occurred in the absence of any indications of oxidative stress. It has been 
demonstrated that ammonia levels >1 mM lead to the generation of ROS in cultured astrocytes and cell swelling [39, 40]. 
Similarly, in vivo, acute ammonia toxicity also leads to oxidative stress in the brain by increasing ROS production and 
diminishing antioxidant enzymes activities [41, 42]. Nevertheless, ammonia concentrations <500 μM have been shown not 
to induce oxidative stress in both astrocyte cultures and brain slices [43, 44]. Furthermore, in both PCA rats and cirrhotic 
rats with brain ammonia levels <250 μM, no signs of oxidative stress in the brain have been identified [27]. However, signs 
of nitrosative stress have been demonstrated in the brains of PCA rats [45] which suggests that nitrosative and oxidative 
stress may be implicated in different stages of HE and/or disease. Furthermore, there is strong evidence demonstrating that 
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oxidative stress in the brain is associated with severe (overt) HE. Both acute ammonia intoxication and acute liver leading to 
severe HE and coma in rats [45-47], as well as cirrhotic patients who died with severe HE (grades III or IV) [48], markers of 
oxidative stress were detected in the brain. Overall, this suggests that the appearance of oxidative stress in the brain may be 
a vital stimulating factor in the pathogenesis of severe, overt HE. 
The blood-brain barrier (BBB) is a structural barrier which impedes the influx of neurotoxic compounds from blood to 
brain. It has been previously demonstrated that circulating ROS can induce BBB oxidative damage and lead to tight junction 
protein modifications, resulting in BBB breakdown, as observed in stroke or sepsis [49]. However, in different animal 
models of covert HE, the BBB has been proven to be anatomically intact [11, 27]. This implies, in the setting of CLD, that 
ROS may not be causing structural breakdown to the BBB, but rather, through oxidative modifications of proteins and 
lipids, may stimulate changes in BBB signalling and permeability. These pathophysiological mechanisms merit to be 
investigated in relation systemic oxidative stress and the development of brain oedema in HE. 
In the present study, we assessed oxidative stress and brain oedema in the frontal cortex; an important region for cognitive 
function. However, the heterogeneity of the brain does not insinuate all areas of the brain react similarly. In fact, the 
cerebellum has demonstrated to have an enhanced susceptibility to oxidative stress in hyperammonaemic rats [46]. 
Therefore, we do not exclude the possibility that other cerebral regions are affected. 
During end stage liver disease, multiple factors other than ammonia and oxidative stress may also be contributing to the 
pathogenesis of brain oedema. Inflammation is an important factor, demonstrated to play an important role in inducing brain 
oedema [50] and known to play an important role in the cognitive and motor alterations in PCA rats [13, 51]. Although 
inflammation is believed to be tightly associated with oxidative stress, their relationship remains unresolved. Other factors 
such as alterations of energy metabolism, osmotic changes triggered by increases in glutamate, glutamine, lactate or 
expression in water or ion channels have also been demonstrated to play a role in brain oedema during liver disease, as 
reviewed by Bosoi and Rose [5]. Neither DEM-treated or untreated PCA rats demonstrated any affects in liver function, 
which excludes the roles of the above-mentioned factors, which have been found to be induced from the ailing liver during 
disease [52]. 
In conclusion, our study confirms that chronic hyperammonaemia and systemic (not central) oxidative stress independently 
do not lead to the development of brain oedema; however, when both factors are present, they act synergistically to induce 
an increase in brain water. The presence of brain oedema in covert HE may be a predisposing factor leading to a higher risk 
of triggering oxidative stress in the brain and developing overt HE. These results support that in addition to targeting 
ammonia producing/removing pathways, antioxidants or pro-oxidant inhibitors should be considered for the treatment of 
HE. 
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